Corpus overview


Overview

MeSH Disease

Human Phenotype

Blindness (1)


Transmission

Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Effectiveness of extracorporeal blood SERO purification (hemoadsorption) in patients with severe coronavirus disease MESHD 2019 (COVID-19) 

    Authors: Masoumeh Asgharpour; Hamed Mehdinezhad; Masoumeh Bayani; Mahmoud Sadeghi Haddad Zavareh; Seyed Hossein Hamidi; Roghayyeh Akbari; Reza Ghadimi; Ali Bijani; Simin Mouodi

    doi:10.21203/rs.3.rs-29229/v2 Date: 2020-05-14 Source: ResearchSquare

    BackgroundExtracorporeal blood SERO purification has been proposed as one of the therapeutic approaches in patients with c oronavirus infection, MESHD because of its beneficial impact on elimination of inflammatory cytokines. MethodsThis controlled trial has been conducted on critically ill COVID-19 patients admitted in the state hospital affiliated to Babol University of Medical Sciences, Iran who received different antiviral and antibacterial drugs, and different modalities of respiratory treatments and did not have positive clinical improvement. No randomization and blindness HP lindness MESHDwas considered. All of the participants underwent three sessions of resin-directed hemoperfusion using continuous renal replacement therapy with a mode of continuous venovenous hemofiltration (CVVH). ResultsFive men and five women with a mean age TRANS of 57.30±18.07 years have been enrolled in the study; and six of them have improved after the intervention. Peripheral capillary oxygen saturation (SpO2) changed after each session. Mean SpO2 before the three sessions of hemoperfusion was 89.60%±3.94% and increased to 92.13%±3.28% after them (p<0.001). Serum SERO IL-6 showed a reduction from 139.70±105.62 to 72.06±65.87 pg/mL (p=0.073); and c-reactive protein decreased from 136.25±84.39 to 78.25±38.67 mg/L (P=0.016).ConclusionsExtracorporeal hemoadsorption could improve the general condition in most of recruited patients with severe c oronavirus disease; MESHD however, large prospective multicenter trials in carefully selected patients are needed to definitely evaluate the efficacy of hemoperfusion in COVID-19 patients.Trial registrationThe research protocol has been registered in the website of Iranian Registry of Clinical Trials with the reference number IRCT20150704023055N2. 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.